Allogene Therapeutics
ALLO
174 hedge funds and large institutions have $385M invested in Allogene Therapeutics in 2024 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 64 increasing their positions, 43 reducing their positions, and 16 closing their positions.
88% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 16
49% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 43
24% more call options, than puts
Call options by funds: $392K | Put options by funds: $317K
8% more funds holding
Funds holding: 161 → 174 (+13)
1.52% more ownership
Funds ownership: 77.6% → 79.12% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
34% less capital invested
Capital invested by funds: $586M → $385M (-$201M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$20.3M |
| 2 |
BlackRock
New York
|
+$20M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.4M |
| 4 |
PA
Perceptive Advisors
New York
|
+$8.04M |
| 5 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$6.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$4.47M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$3.22M |
| 3 |
JP Morgan Chase
New York
|
-$3.12M |
| 4 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
-$2.06M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.97M |
ALLO Hedge Fund Activity: Q2 2024 in Review
174 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q2 2024, worth a combined $385M — down 34% from $586M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ALLO positions and 16 closed out — a net gain of 14 holders — while 64 added to existing stakes and 43 trimmed.
The largest buyer was Capital World Investors, opening a new position worth an estimated $20.3M. The largest seller was State Street, cutting an estimated $4.47M.
- 174 institutional investors held Allogene Therapeutics (ALLO) as of Q2 2024, up from 161 in Q1 2024.
- Funds reported $385M of Allogene Therapeutics stock for Q2 2024, down 34% quarter-over-quarter.
- 30 funds opened new Allogene Therapeutics positions in Q2 2024 and 16 closed out, a net change of +14 holders.
- The largest Allogene Therapeutics buyer in Q2 2024 was Capital World Investors, an estimated $20.3M added.
- The largest Allogene Therapeutics seller in Q2 2024 was State Street, an estimated $4.47M sold.
Based on aggregated 13F filings for Q2 2024.